SALT LAKE CITY, June 21, 2016 – Elute, Inc.™, an emerging leader in developing a new class of polymer-controlled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections, announced today that Michael J. Cima, Ph.D., Professor of Materials Science and David H. Koch Professor of Engineering at the Massachusetts Institute of Technology, was appointed to its Board of Directors. Dr. Cima’s addition to the Elute Board comes at a time when the Company transitions from the pre-clinical stage to the clinical stage of evaluating its novel antibiotic eluting bone void fillers for prevention and treatment of bone infections, prior to its commercial launch.

Dr. Cima is a pioneer in and an accomplished innovator of medical products and materials engineering technologies used for drug delivery and diagnostics. He also has, extensive entrepreneurial experience, having co-founded Microchips Biotech, a developer of microelectronic-based drug delivery and diagnostic systems, T-2 Biosystems, a medical diagnostics company, and Taris Biomedical, a company focused on developing new treatments for difficult-to-treat bladder disease, amongst others. “We are very pleased that he has joined Elute’s Board,” said Ashok C. Khandkar, Ph.D., Chief Executive Officer of Elute. “Michael’s broad experience has particular relevance for Elute at this time, as we move forward towards the first-in-man clinical evaluations of our products. His success as a strategic thinker will add to the depth of our Board as we transition Elute from research and development into a clinical stage company.”

As the David H. Koch Professor of Engineering, Dr. Cima has significant experience in developing successful medical devices that address major unmet medical needs through innovative materials processing and drug delivery technologies. He earned a B.S. in chemistry in 1982 (Phi Beta Kappa) and a Ph.D. in chemical engineering in 1986, both from the University of California at Berkeley. Prof. Cima joined the MIT faculty in 1986 as an Assistant Professor and was promoted to full Professor in 1995. He was elected a Fellow of the American Ceramics Society in 1997 and was elected to the National Academy of Engineering in 2011.

“Elute’s technology employs patented and patent-pending polymer – ceramic composites to address one of the biggest problems in treating bone infections worldwide – delivering a controlled and sustained level of antibiotics within a therapeutic window for 6- 8 weeks,” commented Dr. Cima. “I am pleased to work with Elute’s exceptional team to realize the promise of its technology and help transform the Company into a commercial business that creates lasting value and makes an important difference in the lives of patients and families globally.”

“I also look forward to Dr. Cima’s contributions to our Board and to working with him as we further develop and execute the Company’s strategy to become a global leader in controlled and sustained delivery of antibiotics for treatment of bone infections,” said Dennis B. Farrar, Executive Chairman and co-founder of Elute.

About Elute, Inc.™
Elute, Inc.™ is a private medical device company developing innovative polymercontrolled drug delivery devices designed to prevent and treat orthopedic and other surgical bone infections. Elute’s products provide a clinically relevant delivery of antibiotics and other therapeutic agents directly into surgical sites of patients undergoing orthopedic and other procedures. Elute’s first product candidate, ElutiBoneTM, has demonstrated the controlled release of certain antibiotics in a therapeutic range for a 6-8 week period. The Company has assembled a strong management team, Board of Directors and Clinical Advisory Board with significant clinical and commercial development experience. Elute, Inc. is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.elutinc.com.

Company Contact:
Ashok C Khandkar, PhD,
CEO
Elute, Inc.™
[email protected]